-
Mashup Score: 0Binimetinib: Combination Insights on the Treatment Strate... - 1 year(s) ago
iFrame is not supported! Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD This particular study is a phase 1/2 trial of Pembrolizumab in combination with Binimetinib (brand name MEKTOVI), which is a MEK inhibitor. So previous precl…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Invasive Lobular Breast Cancer: Steffi Oesterreich Shares... - 1 year(s) ago
iFrame is not supported! Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session c…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Attention all medical professionals and those passionate about breast cancer research! Dr. Steffi Oesterreich recently shared insightful learning sessions exploring ILBC at SABCS 2022. @oesterreichs @PittTweat #SABCS22 Read and Share the Article Here: https://t.co/TFAABNUZZP https://t.co/JnzcUEb9nx
-
-
Mashup Score: 0Adipocyte Vaccine: Presents Promising Results for Patient... - 1 year(s) ago
Adipocyte Vaccine: Presents Promising Results for Patients with Breast Cancer at SABCS 2022 Nora Disis MD By Nora Disis, MD Obesity is a major problem and a major cause of cancer, and there’s a particular type of obesity called inflammatory obesity where patients develop metabolic dysfunction. This dysfunction is re…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Promising results for an adipocyte vaccine in the treatment of breast cancer. The video features Dr. Nora Disis, who presented the latest findings at the SABCS 2022. @DrNDisis @UWCancerVaccine #SABCS22 Listen and Share the Audio Podcast Here: https://t.co/T0kYuBH7ob https://t.co/QYXwj52meQ
-
-
Mashup Score: 0Binimetinib: Combination Insights on the Treatment Strate... - 1 year(s) ago
Binimetinib: Combination Insights on the Treatment Strategy of Breast Cancer from SABCS 2022 Saranya Chumsri MD By Saranya Chumsri, MD This particular study is a phase 1/2 trial of Pembrolizumab in combination with Binimetinib (brand name MEKTOVI), which is a MEK inhibitor. So previous preclinical and clinical studi…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting new insights on the treatment strategy of breast cancer have just been shared by Dr. Saranya Chumsri at SABCS 2022. @SaranyaChumsri @MayoClinic #SABCS22 Watch and Share the Video Here: https://t.co/2DPQc3N7jv https://t.co/ckZnhCH1Yq
-
-
Mashup Score: 0Invasive Lobular Breast Cancer: Steffi Oesterreich Shares... - 1 year(s) ago
Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session called Challenging Types o…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Steffi Oesterreich recently shared insightful learning sessions exploring invasive lobular breast cancer (ILBC) at SABCS 2022. @oesterreichs @PittTweat #SABCS22 Watch and Share the Video Here: https://t.co/Yuqzp1aUQ9 https://t.co/h7hfuFIgSm
-
-
Mashup Score: 0
Background: Recent studies suggest differences in outcomes among patients (pts) with metastatic breast cancer (MBC) treated with abemaciclib, ribociclib, or palbociclib, but whether these differences have a genomic basis is unknown. Here, we utilize a large real-world dataset to compare the mutational landscapes of HR+/HER2- MBC samples in which CDK4/6 inhibitor (CDK4/6i) treatment was initiated…
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet-
Mutational Landscape of 1172 Pts w/ HR+, HER2- Met Breast Cancer Tx'd w/ CDK4/6 Inhibitors [Dec 2022] Shah et al. #SABCS22 https://t.co/il0kHWVY58 #bcsm #PrecisionMedicine @TempusLabs https://t.co/RBkLPjBz0Z
-
-
Mashup Score: 3‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP - The ASCO Post - 1 year(s) ago
Jame Abraham, MD, FACP Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP https://t.co/ESgPMVpBRR #bcsm #breastcancer #SABCS22 @SABCS @jamecancerdoc @ClevelandClinic
-
-
Mashup Score: 0FLEX Trial Breast Cancer: SABCS 2022 Mehran Habibi MD Loo... - 1 year(s) ago
FLEX Trial Breast Cancer: SABCS 2022 Mehran Habnibi MD Looking at Gene Mutations By Mehran Habibi, MD, MBA The new adjuvant hormone therapy and to treat the breast cancers that are estrogen positive in the US is not really something that we do a lot. So we do a lot of new adjuvant chemotherapies, but the new adjuvan…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exciting insights on the FLEX trial for breast cancer at #SABCS22 by Dr. Habibi, about gene mutations and how they affect the results of treatment shows how important personalized medicine. @JHBreastGyn @JohnsHopkins Listen and Share the Podcast Here: https://t.co/C09whBAUE8 https://t.co/c25xls42OO
-
-
Mashup Score: 1Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo T... - 1 year(s) ago
Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), which is a novel antibody d…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
OncologyTube features Dr. Sara Tolaney discussing sacituzumab govitecan versus chemotherapy in treating metastatic TNBC. Don't miss out on this talk from a leading oncologist! @stolaney1 @DanaFarber #SABCS22 Listen and Share the Audio Podcast Here: https://t.co/B2XBueIQSc https://t.co/A8yfsk4i92
-
-
Mashup Score: 0Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo T... - 1 year(s) ago
iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the TROPiCS-02 trial? So this year at San Antonio, we saw data from TROPiCS-02. This was a randomized phase 3 study that compared Sacituzumab Govitecan (SG), wh…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
OncologyTube features Dr. Sara Tolaney discussing sacituzumab govitecan versus chemotherapy in treating metastatic TNBC. Don't miss out on this informative talk from a leading oncologist! @stolaney1 @DanaFarber #SABCS22 Read and Share the Article Here: https://t.co/qon7ZzDnrB https://t.co/mB4moUtMMU
-
Exciting new insights on the treatment strategy of breast cancer have just been shared by Dr. Saranya Chumsri at SABCS 2022. @SaranyaChumsri @MayoClinic #SABCS22 Read and Share the Article Here: https://t.co/TXtzvFPzUb https://t.co/aCGMbfq47f